Prognostic role of microRNA-21 in non-small cell lung cancer: a meta-analysis.

INTRODUCTION Many studies have reported that microRNA-21 (miR-21) mihght predict the survival outcome in non-small cell lung cancers (NSCLCs) but the opposite opinion has also been expressed. The aim of this study was to summarize the evidence for a prognostic role of miR-21. MATERIALS AND METHODS All the eligible studies was searched by Medline and EMBASE and patients' clinical characteristics and survival outcome were extracted. Then a meta-analysis was performed to clarify the prognostic role of the miR-21 expression in different subgroups. RESULTS A total of 8 eligible articles were yielded covering survival outcomes or clinical characteristics. The combined hazard ratio (HR) and 95% confidence interval (95% CI) for overall survival (OS) was 2.19 [0.76, 6.30], while the combined HR (95% CI) of Asian group for OS had a significant result, 5.49 [2.46, 12.27]. The combined HR (95% CI) for recurrence free survival or disease free survival (RFS/DFS) was 2.31 [1.52, 3.49]. Odds ratios (ORs) showed that the miR-21 expression was associated with lymph node status and histological type. CONCLUSION miR-21 expression could predict the prognostic outcome of NSCLC in Asians, despite some deficiencies in the study data.

[1]  H. Shen,et al.  A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Xiao-guang Liu,et al.  High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer , 2012, Medical Oncology.

[3]  W. De,et al.  Prognostic significance of serum miRNA‐21 expression in human non‐small cell lung cancer , 2011, Journal of surgical oncology.

[4]  Junming Yue,et al.  MicroRNA miR-21 Regulates the Metastatic Behavior of B16 Melanoma Cells* , 2011, The Journal of Biological Chemistry.

[5]  M. Rodicio,et al.  Analytical aspects of microRNA in diagnostics: a review. , 2011, Analytica chimica acta.

[6]  Yi Zhu,et al.  Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer , 2011, Chinese journal of cancer.

[7]  Vidar Skaug,et al.  The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non–Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three Cohorts , 2011, Clinical Cancer Research.

[8]  Y. Shu,et al.  MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis , 2011, Journal of Cancer Research and Clinical Oncology.

[9]  Jane J. Sohn,et al.  MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. , 2010, Cancer research.

[10]  H. Nielsen,et al.  High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients , 2010, Clinical & Experimental Metastasis.

[11]  E. Olson,et al.  Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. , 2010, Cancer cell.

[12]  Yue Yu,et al.  Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. , 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  Guanghai Yang,et al.  MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). , 2010, Clinica chimica acta; international journal of clinical chemistry.

[14]  Ruian Xu,et al.  Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. , 2009, Current cancer drug targets.

[15]  B. Qian,et al.  High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1 , 2009, Breast Cancer Research and Treatment.

[16]  R. Vessella,et al.  Molecular assays for the detection of microRNAs in prostate cancer , 2009, Molecular Cancer.

[17]  Yu Liang.  An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer , 2008, BMC Medical Genomics.

[18]  Vassilis Georgoulias,et al.  Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. , 2008, Clinical chemistry.

[19]  N. Colburn,et al.  MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene , 2008, Oncogene.

[20]  Shamit Soneji,et al.  Microrna expression distinguishes between germinal center B cell‐like and activated B cell‐like subtypes of diffuse large B cell lymphoma , 2007, International journal of cancer.

[21]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[22]  Sven Diederichs,et al.  Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. , 2006, Cancer research.

[23]  D. Bartel,et al.  Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs , 2004, Nature Reviews Genetics.

[24]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[25]  C. Isaacs,et al.  Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[26]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[27]  Paula R Williamson,et al.  Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.

[28]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[29]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[30]  S. Ramalingam,et al.  Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Sleight,et al.  Publication bias , 1991, The Lancet.

[32]  J. Cornfield,et al.  A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. , 1951, Journal of the National Cancer Institute.